Search Result

Isoforms Recommended:	CDK9

Results for "

CDK9

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (32) Bcl-2 Family (1) c-Myc (1) Casein Kinase (2) CDK (116) Cholinesterase (ChE) (1) CMV (2) EGFR (3) Epigenetic Reader Domain (1) ERK (1) FLT3 (2) Fungal (1) GSK-3 (3) HDAC (1) HIV (3) IRE1 (1) JAK (2) Ligands for Target Protein for PROTAC (4) MEK (2) Molecular Glues (2) PKC (1) PROTACs (12) Reactive Oxygen Species (1) SARS-CoV (1) Small Interfering RNA (siRNA) (3) Virus Protease (1)
By Research Areas:	Cancer (117) Infection (5) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (2)

By Targets:

Antibiotic (1)

Apoptosis (32)

Bcl-2 Family (1)

c-Myc (1)

Casein Kinase (2)

CDK (116)

Cholinesterase (ChE) (1)

CMV (2)

EGFR (3)

Epigenetic Reader Domain (1)

ERK (1)

FLT3 (2)

Fungal (1)

GSK-3 (3)

HDAC (1)

HIV (3)

IRE1 (1)

JAK (2)

Ligands for Target Protein for PROTAC (4)

MEK (2)

Molecular Glues (2)

PKC (1)

PROTACs (12)

Reactive Oxygen Species (1)

SARS-CoV (1)

Small Interfering RNA (siRNA) (3)

Virus Protease (1)

By Research Areas:

Cancer (117)

Infection (5)

Inflammation/Immunology (1)

Metabolic Disease (1)

Neurological Disease (2)

132

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

CDK9 inhibitor HH1	CDK	Cancer
CDK9 inhibitor HH1 is a potent and selectively *CDK9* inhibitor. CDK9 inhibitor HH1 inhibits the transcription of CDK. CDK9 inhibitor HH1 can be used in research of cancer .

CDK9 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDK9 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk9 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cdk9 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk9 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk9 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cdk9 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk9 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK9-IN-18	CDK Apoptosis	Cancer
CDK9-IN-18 is a potent *CDK9* inhibitor. CDK9-IN-18 blocks the phosphorylation function of kinase CDK9. CDK9-IN-18 exhibits both good anticancer activity and low cellular activity. CDK9-IN-18 induces apoptosis.

CDK9-IN-10	CDK Ligands for Target Protein for PROTAC	Cancer
CDK9-IN-10 is a potent *CDK9* inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811) .

CDK9-IN-9	CDK	Cancer
CDK9-IN-9 (example 2) is a potent and selective *CDK9* inhibitor with an IC₅₀ of 1.8 nM. CDK9-IN-9 inhibits CDK2 with an IC₅₀ of 155 nM. CDK9-IN-9 has anti-cancer activity .

CDK9-IN-29	CDK	Cancer
CDK9-IN-29 (compound Z11) is a potent *CDK9* inhibitor (IC₅₀ = 3.20 nM) with good kinase selectivity. CDK9-IN-29 inhibits cell proliferation and induces apoptosis .

CDK9-IN-24	Apoptosis CDK	Others
CDK9-IN-24 (compound 21a) is a highly selective *CDK9* inhibitor with significant inhibitory effect on tumor growth. CDK9-IN-24 effectively blocks cell proliferation and induces apoptosis by downregulating Mcl-1 and c-Myc, and can be used in acute myeloid leukemia research .

CDK9-IN-32	CDK	Cancer
CDK9-IN-32 (compound 006-3) is a *CDK9* inhibitor .

CDK9-IN-19	CDK	Cancer
CDK9-IN-19 is a highly potent and selective *CDK9* inhibitor with an IC₅₀ value of 2.0 nM. CDK9-IN-19 has excellent cellular antiproliferative activity, moderate pharmacokinetic property and low hERG inhibition. CDK9-IN-19 significantly induces tumour growth inhibition in an MV4-11 xenograft mice model. CDK9-IN-19 can be used for researching acute myeloid leukaemia (AML) .

CDK9-IN-14	CDK	Cancer
CDK9-IN-14 is a potent and selective *CDK9* inhibitor with IC₅₀ of 6.92 nM. CDK9-IN-14 has a relatively strong inhibitory effect on MV4;11 cells and in vivo tumor models, and has a good selectivity and a low toxicity and few side effects .

CDK9-IN-11	CDK Ligands for Target Protein for PROTAC	Cancer
CDK9-IN-11 is a potent *CDK9* inhibitor. CDK9-IN-11 is the ligand for the PROTAC CDK9 Degrader-1 (HY-103628) .

CDK9-IN-22	CDK	Cancer
CDK9-IN-22 is a potent *CDK9* inhibitor with IC₅₀s of 10.4, 876.2 nM for CDK9, CDK, respectively. CDK9-IN-22 induces apoptosis and cell cycle arrests at G2/M phase. CDK9-IN-22 decreases the expression of p-RNAPII (S2) and CDK9 protein. CDK9-IN-22 shows antiproliferative and aiti-tumor activity .

CDK9-IN-13	CDK	Cancer
CDK9-IN-13 (compound 38) is potent and selective *CDK9* inhibitor, with an IC₅₀ of <3 nM. CDK9-IN-13 exhibits short half-lives in rodents .

CDK9-IN-31	CDK	Cancer
CDK9-IN-31 (Compound Z1) is a *CDK9* inhibitor that inhibits cancer cell growth. CDK9-IN-31 has the potential to be developed as an anticancer agent .

CDK9-IN-15	CDK	Cancer
CDK9-IN-15 (compound 50) is a potent *CDK9* inhibitor .

CDK9-IN-1 2 Publications Verification	CDK HIV	Infection
CDK9-IN-1 is a novel, selective *CDK9* inhibitor for the treatment of HIV infection, with an IC₅₀ of 39 nM for CDK9/CycT1, extracted from reference, compound 87.

CDK9-IN-8	CDK	Cancer
CDK9-IN-8 is a highly effective and selective *CDK9* inhibitor with an IC₅₀ of 12 nM.

CDK9-IN-23	CDK	Cancer
CDK9-IN-23 (Example 4) is a *CDK9* inhibitor with an IC₅₀ of <20 nM .

CDK9-IN-12	CDK	Cancer
CDK9-IN-12 displays the optimal *CDK9* inhibitory activity with an IC₅₀ value of 5.41 nM.

CDK9-IN-30	CDK HIV	Infection
CDK9-IN-30 is a CDK9 inhibitor that inhibits HIV-1 viral replication .

CDK9-IN-27	CDK	Cancer
CDK9-IN-27 (Compound 6a) is a *CDK9* inhibitor (IC₅₀s: 0.424 μM). CDK9-IN-27 induces apoptosis and cell cycle arrest at S stage. CDK9-IN-27 has cytotoxic action against HepG2, HCT-116 and MCF-7 cell lines, with IC₅₀s of 10.31-40.34 μM. CDK9-IN-27 can be used for cancer research .

CDK9-IN-31 dimaleate	CDK	Cancer
CDK9-IN-31 dimaleate (Compound Z1) is a *CDK9* inhibitor that inhibits cancer cell growth. CDK9-IN-31 dimaleate has the potential to be developed as an anticancer agent .

CDK9-IN-26	CDK	Cancer
CDK9-IN-26 (compound 1is a CDK9 inhibitor (IC₅₀=0.18 μM)。 .

CDK9-IN-28	CDK	Cancer
PROTAC CDK9/CycT1 Degrader-1 (compounds 10) is a potent inhibitor of *CDK9. PROTAC CDK9/CycT1 Degrader-1 can be used as a PROTAC* target protein ligand for PROTAC synthesis. PROTAC CDK9/CycT1 Degrader-1 shows strong anti-proliferative activity in solid tumors .

CDK9-IN-25	CDK SARS-CoV Virus Protease	Infection
CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC₅₀: 0.24 μM). CDK9-IN-25 has good affinity to the main protease of COVID-19 and has antiviral activity against human coronavirus 229E (IC₅₀: 63.28 μM) .

CDK9-IN-7	CDK Apoptosis	Cancer
CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC₅₀=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC .

CDK9-Cyclin T1 PPI-IN-1	CDK Apoptosis	Cancer
CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective CDK9-Cyclin T1 protein-protein interaction (PPI) inhibitor. CDK9-Cyclin T1 PPI-IN-1 inhibits cell proliferation in TNBC MDA-MB-231 cells (IC₅₀: 0.044 μM), and induces apoptosis. CDK9-Cyclin T1 PPI-IN-1 inhibits CDK9 transcription activity, reduces the phosphorylation of RNA Pol II CTD ser2. CDK9-Cyclin T1 PPI-IN-1 inhibits tumor growth in a TNBC 4T1 mouse model .

CDK9-IN-2 5 Publications Verification	CDK	Cancer
CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC₅₀ of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.

CDK9/10/GSK3β-IN-1	Others	Cancer
CDK9/10/GSK3β-IN-1 (compound 13c) is a kinase inhibitor (Flavopiridol (HY-10005) analogue) that effectively inhibits HsGSK3β (IC₅₀=59 nM), *HsCDK9/CyclinT* (IC₅₀=64 nM), HsCDK5/p25 (IC₅₀=1.093 µM) and HsCDK2/CyclinA (IC₅₀=1.725 µM). CDK9/10/GSK3β-IN-1 has anti-cancer cellular activity comparable to or higher than that of Flavopiridol. CDK9/10/GSK3β-IN-1 shows high anti-proliferative activity in vitro against up to seven cancer cell lines .

*PROTAC CDK9* degrader-7**	CDK	Cancer
PROTAC CDK9 degrader-7 is a PROTAC targeting to *CDK9* sepcifically. PROTAC CDK9 degrader-7 mediates CDK9 degradation via the proteasome .

*PROTAC CDK9* degrader-5**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-5 is a PROTAC targeting to *CDK9* sepcifically. PROTAC CDK9 degrader-5 mediates CDK9 degradation via the proteasome. PROTAC CDK9 degrader-5 degrades CDK9 with DC₅₀s of 0.10 μM and 0.14 μM for the CDK9₄₂ and CDK9₅₅ isoforms, respectively .

*PROTAC CDK9* degrader-6**	CDK	Cancer
PROTAC CDK9 degrader-6 is a PROTAC targeting to *CDK9* sepcifically. PROTAC CDK9 degrader-6 mediates CDK9 degradation via the proteasome. PROTAC CDK9 degrader-6 degrades CDK9 with DC₅₀s of 0.10 μM and 0.14 μM for the CDK9₄₂ and CDK9₅₅ isoforms, respectively .

*PROTAC CDK9* ligand-1**	Ligands for Target Protein for PROTAC	Cancer
PROTAC CDK9 ligand-1 is a *CDK9* ligand that can be used in the synthesis of PROTACs.

*PROTAC CDK9* degrader-8**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-8 (compound 21) is a potent PROTAC CDK9 degrader with an IC₅₀ value of 0.01 μM. PROTAC CDK9 degrader-8 can be used in research of cancer .

*PROTAC CDK9* Degrader-1** 1 Publications Verification	PROTACs CDK	Cancer
PROTAC CDK9 Degrader-1 is a PROTAC connected by ligands for Cereblon and *CDK* as a selective *CDK9* degrader.

*PROTAC CDK9* degrader-4**	PROTACs	Cancer
PROTAC CDK9 degrader-4 is a highly potent and efficacious *CDK9* degrader for targeting transcription regulation.

*(R)-PROTAC CDK9* ligand-1**	Ligands for Target Protein for PROTAC CDK	Cancer
(R)-PROTAC CDK9 ligand-1 (Compound 19.4) is a *CDK9*-targeting degrader that can be used to synthesize PROTAC with antitumor activity .

*PROTAC CDK9* degrader-2**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-2 (compound 11c) is a potent and selective *CDK9* degrader based on PROTAC, with an IC₅₀ of 17 μM in MCF-7 cell lines. Natural product Wogonin (CDK ligand) binds ubiquitin E3 ligase Cereblon (CRBN) via a linker to form PROTAC .

*PROTAC CDK9/CycT1 Degrader-2*	CDK	Cancer
PROTAC CDK9/CycT1 Degrader-2 is a inhibitor of *CDK9, with the IC₅₀* of 45 nM .

*EGFR/HER2/CDK9-IN-2*	EGFR CDK	Cancer
EGFR/HER2/CDK9-IN-2 (Compound 9) is a potent inhibitor of EGFR/HER2/CDK9 with IC₅₀*s of 145.35, 129.07, and 117.13 nM, respectively. EGFR/HER2/CDK9-IN-2 exhibits remarkable antitumor activity .*

*EGFR/HER2/CDK9-IN-3*	EGFR CDK	Cancer
EGFR/HER2/CDK9-IN-3 (Compound 10) is a potent inhibitor of EGFR/HER2/CDK9 with IC₅₀*s of 191.08, 132.65, and 113.98 nM, respectively. EGFR/HER2/CDK9-IN-3 exhibits remarkable antitumor activity .*

*EGFR/HER2/CDK9-IN-1*	EGFR CDK	Cancer
EGFR/HER2/CDK9-IN-1 (Compound 4) is a potent inhibitor of EGFR/HER2/CDK9 with IC₅₀*s of 90.17, 131.39, and 67.04 nM, respectively. EGFR/HER2/CDK9-IN-1 exhibits remarkable antitumor activity .*

*PROTAC FLT3/CDK9* degrader-1**	CDK FLT3 PROTACs Apoptosis	Cancer
PROTAC FLT3/CDK9 degrader-1 is a potent FLT3 and *CDK9* dual PROTAC degrader. PROTAC FLT3/CDK9 degrader-1 induces apoptosis and effective degradation of target proteins FLT3 and CDK9. PROTAC FLT3/CDK9 degrader-1 has the potential for the research of FLT3-ITD mutated AML .

KB-0742 dihydrochloride	CDK	Cancer
KB-0742 dihydrochloride is a potent, selective and orally active *CDK9* inhibitor with an IC₅₀ of 6 nM for CDK9/cyclin T1. KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity .

Cat. No.	Product Name	Target	Research Area

HY-P2559

CDK7/9 tide

CDK Cancer

CDK7/9 tide is peptide substrate for CDK7 or CDK9 .

Species:	Human (6)
Tag:	His (2) Tag Free (3) GST (3) Flag (2)
Source:	Sf9 insect cells (6)

Cat. No.	Compare	Product Name	Species	Source

HY-P701374

	CDK9-CCNK Heterodimer Protein, Human (Sf9) CDK9; CCNK; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-K	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNK Heterodimer Protein, Human (Sf9) is a recombinant protein dimer complex containing human-derived CDK9-CCNK Heterodimer protein, expressed by Sf9 insect cells , with tag free.

HY-P701375

	CDK9-CCNK Heterodimer Protein, Human (Sf9, GST, FLAG) CDK9; CCNK; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-K	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNK Heterodimer Protein, Human (Sf9, GST, FLAG) is a recombinant protein dimer complex containing human-derived CDK9-CCNK Heterodimer protein, expressed by Sf9 insect cells , with N-Flag, N-GST labeled tag.

HY-P702689

	CDK9-CCNT1 Protein, Human (sf9, GST, His) CDK9; CCNK; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-K	Human	Sf9 insect cells

HY-P702690

	CDK9-CCNT2 Protein, Human (sf9, GST, Flag, His) CDK9; CCNK; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-K	Human	Sf9 insect cells

HY-P701377

	CDK9-CCNT2 Heterodimer Protein, Human (Sf9) CDK9; CCNT2; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-T2; CycT2	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNT2 Heterodimer Protein, Human (Sf9) is a recombinant protein dimer complex containing human-derived CDK9-CCNT2 Heterodimer protein, expressed by Sf9 insect cells , with tag free.

HY-P701376

	CDK9-CCNT1 Heterodimer Protein, Human (Sf9) CDK9; CCNT1; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-T1; CycT1; Cyclin-T	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNT1 Heterodimer Protein, Human (Sf9) is a recombinant protein dimer complex containing human-derived CDK9-CCNT1 Heterodimer protein, expressed by Sf9 insect cells , with tag free.

Cat. No.	Product Name	Application	Reactivity

HY-P80614

CDK9 Antibody TAK; C-2k; CTK1; CDC2L4; PITALRE	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat
CDK9 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 43 kDa, targeting to CDK9. It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks